海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
32件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- Dexmedetomidine for saphenous nerve blockade in patients undergoing anterior cruciate ligament replacement: a randomized, placebo-controlled, triple blinded study
- Dexmedetomidine -a selective alpha-2-receptor agonist- added to a local anaesthetic (ropivacaine) should prolong a saphenous block and the patients demand for the first analgesic. We designed a prospective, controlled, randomized, triple-blinded study with 40 patients parted into 2 groups who have to undergo anterior cruciate ligament reconstruction. Group R receives 10ml Ropivacaine 7.5mg/ml, group R%100DEX receives 10ml Ropivacaine 7,5mg/ml with 100µg Dexmedetomidine.;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
- Austria
- 2014-10-30
Authorised
- Comparison of Treosulfan-based with Busulfan-based conditioning in paediatric patients with non-malignant diseases
- Male and female children with non-malignant diseases requiring myeloablative conditioning treatment with following allogeneic haematopoietic stem cell transplantation (allo-HSCT) – i.e. primary immunodeficiencies, inborn errors of metabolism, haemoglobinopathies and bone marrow failure syndromes. MedDRA version: 20.0 Level: HLT Classification code 10021606 Term: Inborn errors of metabolism NEC System Organ Class: 100000004850 MedDRA version: 20.0 Level: HLT Classification code 10036700 Term: Primary immunodeficiency syndromes System Organ Class: 100000004870 MedDRA version: 20.0 Level: HLT Classification code 10018903 Term: Haemoglobinopathies congenital System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Austria, Czech Republic, Germany, Italy, Poland
- 2014-06-06
